79983-34-9 Usage
Uses
Used in Pharmaceutical Industry:
2-(chloromethyl)-1,4,5,6-tetrahydropyrimidine serves as a key precursor in the development of various drugs. Its unique structure allows for the creation of heterocyclic compounds, which are often found in medicinal chemistry, contributing to the compound's potential in drug discovery and medicinal applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(chloromethyl)-1,4,5,6-tetrahydropyrimidine is utilized as a starting material for the synthesis of agrochemicals. Its reactivity and functional group compatibility facilitate the production of compounds that can be used in the development of pesticides and other agricultural chemicals.
Used in Organic Synthesis:
2-(chloromethyl)-1,4,5,6-tetrahydropyrimidine is employed as a versatile reagent in organic synthesis. Its ability to form heterocyclic compounds and participate in various chemical reactions makes it a valuable component in the synthesis of a wide range of organic molecules.
Used in Research and Development:
2-(chloromethyl)-1,4,5,6-tetrahydropyrimidine is also used in research and development settings to explore new chemical reactions and syntheses. Its potential applications in creating novel compounds and understanding reaction mechanisms make it an important tool for scientific inquiry.
It is crucial to handle 2-(chloromethyl)-1,4,5,6-tetrahydropyrimidine with care due to its potential health hazards, ensuring safe practices in laboratories and industrial settings.
Check Digit Verification of cas no
The CAS Registry Mumber 79983-34-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,9,9,8 and 3 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 79983-34:
(7*7)+(6*9)+(5*9)+(4*8)+(3*3)+(2*3)+(1*4)=199
199 % 10 = 9
So 79983-34-9 is a valid CAS Registry Number.
79983-34-9Relevant academic research and scientific papers
REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR
-
Paragraph 00193; 00194, (2018/09/12)
A method involving the administration of a therapeutically effective amount of a leukotriene inhibitor, a pharmaceutically acceptable salt, a pharmaceutically acceptable N-oxide, a pharmaceutically active metabolite, a pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof to a human for reducing a level of pro-inflammatory HDL in the human. Various examples of leukotriene inhibitors, including 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin- 3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2, 2-dimethyl-propionic acid, are disclosed for administration for the reduction of pro-inflammatory HDL in a human. Reduction of pro-inflammatory HDL by the leukotriene inhibitor may include conversion of at least a portion of pro-inflammatory HDL to anti-inflammatory HDL.
BETA CARBOLINES AND USES THEREOF
-
Page/Page column 58-59, (2009/06/27)
This invention provides beta-carboline compounds of formula I: wherein R1, R2, R3, R4, R5, G, and x are as described in the specification. The compounds are useful for treating cancer and inflammatory disorders.
5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
-
Page/Page column 64, (2008/06/13)
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
